HEALTHCNBC TOP
Botox maker Galderma sees early boost from 'Ozempic face' trend as GLP-1 use climbs, CEO says
Galderma, a Botox maker, is experiencing an early boost from the 'Ozempic face' trend linked to increased GLP-1 use. The company's CEO expects rising demand for treatments addressing facial volume loss associated with this trend.
Related Signal
Adjacent reporting
- How ‘Ozempic face’ is pushing Gen X, already the biggest Botox and filler consumers, to the facelift table a decade early
- Ozempic nation: America’s GLP-1 use nearly quadruples in just two years
- GLP-1 Craze Fuels Protein-Powder Maker Glanbia’s Share Rally
- Lunch-break Botox: executives turn to ‘tweakments’ to get ahead
- "Ozempic breath" is boosting Hershey's sales of mints and gum
- WATCH: Bridal industry adapts as GLP-1 weight loss drugs alter dress fittings